Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Generex Biotechnology Corp GNBT
(Total Views: 380)
Posted On: 08/13/2021 10:53:29 PM
Post# of 36568
Posted By: rjs9787
Re: youhou #31368
It’s not even a close comparison.

“The vaccine is safe and well tolerated with no grade 3 local toxicities and 1 pt experiencing grade 3 systemic toxicity.”

And that’s for the AE37 vaccine to prevent breast cancer with the immuno-adjuvant GM-CSF. Plus, this is after study investigators at MD Anderson followed the subjects for a couple years. Longer term data at 4 years for AE37 + GM-CSF for prostrate cancer and 10 years for AE37- GM-CSF in the above breast cancer trial confirm both the unique positive safety profile and the long term memory of the vaccine.

The GP2 and NeuVax studies has similar safety profiles with the very mild effect attributed to GM-CSF. Generex signed an agreement with 3M for an adjuvant that they feel is better suited for a Covid vaccine.

The serious local and systematic toxicity attributed to mRNA Covid vaccines is far more serious and nowhere near studied as far out as AE37 studies.













(5)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site